

VIVALIS ANNOUNCES THE PHASE III ADVANCEMENT OF THE EB66[®] CELL BASED HUMAN INFLUENZA VACCINE

Nantes & Lyon (France) –14 September 2012—VIVALIS (NYSE Euronext: VLS) announced today the advancement of a human influenza vaccine into Phase III clinical trials being jointly developed by the Chemo-Sero-Therapeutic Research Institute of Japan (“Kaketsuken”), GlaxoSmithKline K.K. (“GSK Japan”), and GlaxoSmithKline Vaccines (“GSK”).

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “This is a major development for the EB66[®] platform and we are happy that Kaketsuken and GlaxoSmithKline have achieved this significant milestone. EB66[®] is an innovative cell-line that is now used as a production platform for a vaccine that reaches Phase III, the last step of clinical development. Having worked together with GSK and Kaketsuken, over the last several years, it is gratifying for Vivalis to see this investigational product progress using a technology developed with this type of dedication envisioned. We look forward to continuing these relationships and are confident that our EB66[®] technology will continue to provide the demands exacted upon it.”

Next Financial Press Release

23 October 2012, after NYSE Euronext market closing: Third Quarter 2012 Revenues

About VIVALIS (www.vivalis.com)

VIVALIS (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in two main areas:

EB66[®] Cell Line

VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales.

VIVA|Screen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of rare, fully human monoclonal antibodies is offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales under both service agreements and partnered programs.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS, VIVALIS was founded in 1999 by the Grimaud group (ca. 1,700 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi

Pasteur, GlaxoSmithKline, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Intervet, and SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indices



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantees can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

Vivalis

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr